Erlotinib hydrochloride is a small molecule epidermal growth factor receptor tyrosine kinase reversible inhibitor, mainly used for the second or third line treatment of locally advanced or metastatic non-small cell lung cancer and pancreatic cancer.
Erlotinib hydrochloride is a potent, small-molecule tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR). Synthesized via multi-step organic coupling and salt formation, it serves as a critical API for oncology formulations. Its molecular formula is C22H23ClN4O·HCl with CAS No. 183319-69-9.
Strictly indicated for patients with confirmed EGFR mutations; contraindicated for severe hepatic impairment. Store at 20°C–25°C in moisture-proof containers to maintain stability. Handle with PPE to avoid dermal absorption and inhalation risks.